Patents Assigned to AB Pharma Ltd.
  • BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICAL APPLICATION THEREOF
    Publication number: 20230339919
    Abstract: Disclosed in the present invention are a compound represented by formula Ib or IIb, a cis or trans isomer, enantiomer, diastereomer, racemate, tautomer, solvate, hydrate, and pharmaceutically acceptable salt thereof, or a mixture thereof, a pharmaceutical composition containing the compound, and a use of the compound as a GPR40 agonist, wherein n, E, G1, L1, L2, R1, R2, R3, R4, R5, R5b, R6, R7, X5, X6, X7, Y, Y1, Z, Z1, and the possible isotopic substitution label of each element in the compound are as defined in the description.
    Type: Application
    Filed: September 10, 2021
    Publication date: October 26, 2023
    Applicant: AB PHARMA LTD.
    Inventor: Zhengyun ZHAN
  • Antiviral compounds highly effective as HCV-NS5A inhibitor
    Patent number: 9820972
    Abstract: Provided are compounds antiviral compounds represented by formula Ia and Ib: that are highly potent as HCV NS5A inhibitors, where the structural variables are as defined herein. These compounds are useful in, for example, inhibiting Hepatitis C virus and treating Hepatitis C virus infections.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: November 21, 2017
    Assignee: AB PHARMA LTD.
    Inventor: Zheng-Yun James Zhan
  • ANTIVIRAL COMPOUNDS HIGHLY EFFECTIVE AS HCV-NS5A INHIBITOR
    Publication number: 20160136134
    Abstract: Provided are compounds antiviral compounds represented by formula Ia and Ib: that are highly potent as HCV NS5A inhibitors, where the structural variables are as defined herein. These compounds are useful in, for example, inhibiting Hepatitis C virus and treating Hepatitis C virus infections.
    Type: Application
    Filed: January 20, 2016
    Publication date: May 19, 2016
    Applicant: AB PHARMA LTD.
    Inventor: Zheng-Yun James ZHAN
  • Antiviral compounds highly effective as HCV-NS5A inhibitor
    Patent number: 9334291
    Abstract: Provided are compounds antiviral compounds represented by formula Ia and Ib: that are highly potent as HCV NS5A inhibitors, where the structural variables are as defined herein. These compounds are useful in, for example, inhibiting Hepatitis C virus and treating Hepatitis C virus infections.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: May 10, 2016
    Assignee: AB PHARMA LTD.
    Inventor: Zheng-Yun James Zhan
  • Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and use thereof
    Patent number: 8962810
    Abstract: The present invention discloses a class of novel macro-heterocyclic compounds represented by the formula Ia or Ib, and their intermediates, preparation methods and the uses. The macro-heterocyclic compounds of the present invention have good inhibitory activities against hepatitis C virus (HCV), and can be used to treat HCV infection effectively by its excellent inhibition against HCV, low toxicity and side effects.
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: February 24, 2015
    Assignee: AB Pharma Ltd.
    Inventor: Zheng-yun James Zhan
  • ANTIVIRAL COMPOUNDS HIGHLY EFFECTIVE AS HCV-NS5A INHIBITOR
    Publication number: 20140364429
    Abstract: Provided are compounds antiviral compounds represented by formula Ia and Ib: that are highly potent as HCV NS5A inhibitors, where the structural variables are as defined herein. These compounds are useful in, for example, inhibiting Hepatitis C virus and treating Hepatitis C virus infections.
    Type: Application
    Filed: June 6, 2014
    Publication date: December 11, 2014
    Applicant: AB PHARMA LTD.
    Inventor: Zheng-Yun James ZHAN
  • Polyheterocyclic compounds highly potent as HCV inhibitors
    Patent number: 8815796
    Abstract: The present invention discloses the structure, preparation methods and uses of a series of novel polyheterocyclic based compounds (Ia-Ib and IIa-IIb) that are highly effective for inhibiting hepatitis C virus (HCV): where the structural variables are defined herein. The present invention is also provides a method of treating HCV infection by the polyheterocyclic based HCV inhibitory compounds, compositions and therapeutic methods.
    Type: Grant
    Filed: September 3, 2013
    Date of Patent: August 26, 2014
    Assignee: AB Pharma Ltd.
    Inventor: Zheng-Yun James Zhan
  • Macrocyclic Heterocyclic Compound for Inhibiting Hepatitis C Virus and Preparation and Use Thereof
    Publication number: 20140205567
    Abstract: The present invention discloses a class of novel macro-heterocyclic compounds represented by the formula Ia or Ib, and their intermediates, preparation methods and the uses. The macro-heterocyclic compounds of the present invention have good inhibitory activities against hepatitis C virus (HCV), and can be used to treat HCV infection effectively by its excellent inhibition against HCV, low toxicity and side effects.
    Type: Application
    Filed: June 14, 2012
    Publication date: July 24, 2014
    Applicant: AB Pharma Ltd.
    Inventor: Zheng-yun James Zhan
  • Polyheterocyclic compounds highly potent as HCV inhibitors
    Patent number: 8653025
    Abstract: The present invention discloses the structure, preparation methods and uses of a series of novel polyheterocyclic based compounds (Ia-Ib and IIa-IIb) that are highly effective for inhibiting hepatitis C virus (HCV): where the structural variables are defined herein. The present invention is also provides a method of treating HCV infection by the polyheterocyclic based HCV inhibitory compounds, compositions and therapeutic methods.
    Type: Grant
    Filed: January 27, 2011
    Date of Patent: February 18, 2014
    Assignee: AB Pharma Ltd.
    Inventor: Zheng-Yun James Zhan
  • POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS
    Publication number: 20140005104
    Abstract: The present invention discloses the structure, preparation methods and uses of a series of novel polyheterocyclic based compounds (Ia-Ib and IIa-IIb) that are highly effective for inhibiting hepatitis C virus (HCV): where the structural variables are defined herein. The present invention is also provides a method of treating HCV infection by the polyheterocyclic based HCV inhibitory compounds, compositions and therapeutic methods.
    Type: Application
    Filed: September 3, 2013
    Publication date: January 2, 2014
    Applicant: AB Pharma Ltd.
    Inventor: Zheng-Yun James ZHAN
  • POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS
    Publication number: 20110183895
    Abstract: The present invention discloses the structure, preparation methods and uses of a series of novel polyheterocyclic based compounds (Ia-Ib and IIa-IIb) that are highly effective for inhibiting hepatitis C virus (HCV): where the structural variables are defined herein. The present invention is also provides a method of treating HCV infection by the polyheterocyclic based HCV inhibitory compounds, compositions and therapeutic methods.
    Type: Application
    Filed: January 27, 2011
    Publication date: July 28, 2011
    Applicant: AB Pharma Ltd.
    Inventor: Zheng-Yun James ZHAN